Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2279]

Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast...

Dr Jayant Vaidya - University College London, London, UK

Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer ( Dr Jayant Vaidya - University College London, London, UK )

Choosing Wisely in radiology

Dr Iramu Revelian - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology ( Dr Iramu Revelian - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Choosing Wisely in radiotherapy

Dr Sikudhani Muya - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiotherapy ( Dr Sikudhani Muya - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Choosing Wisely in pathology

Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in pathology ( Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Latest in PARP inhibitors and combination therapies for prostate cancer

Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni...

Latest in PARP inhibitors and combination therapies for prostate cancer ( Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni Efstathiou )

3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib...

Dr Mauricio Burotto - Bradford Hill, Recoleta, Chile

3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib for first-line treatment of aRCC ( Dr Mauricio Burotto - Bradford Hill, Recoleta, Chile )

Plasma miR371 detects MRD and early relapse of germ cell tumours

Dr Lucia Nappi - University of British Columbia, Vancouver, Canada

Plasma miR371 detects MRD and early relapse of germ cell tumours ( Dr Lucia Nappi - University of British Columbia, Vancouver, Canada )

ASCO GU 2023: Latest updates in mRCC

Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor...

ASCO GU 2023: Latest updates in mRCC ( Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor Grünwald and Prof Toni Choueiri )

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in...

Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC ( Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France )

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

More from ecancer